Safer and more effective diabetes control with basal insulin analogs

June 24, 2011
Diabetes Technology & Therapeutics is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis and prevention of diabetes and its complications. Credit: ©2011, Mary Ann Liebert Inc., publishers

Basal insulin analogs have revolutionized diabetes care, and especially the treatment of type 2 diabetes, enabling patients to achieve better control of blood glucose levels while reducing hypoglycemic episodes. These revolutionary, long-acting basal insulin analogs, intended to replace the natural insulin missing in diabetes, and infusion pumps that provide subcutaneous, continuous delivery of insulin to mimic the function of a normal pancreas, are described in a special supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc.

More than 25 million people in the U.S. have , and the global diabetes epidemic is estimated to affect nearly 440 million people by 2030. "The development of basal insulin analogs has greatly impacted the management of diabetes," writes Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics and Professor of Medicine and Pediatrics at the University of Colorado Denver, and Emily Moser, University of Colorado Denver School of Medicine, in their Editorial introducing the broad scope of articles in this issue that detail the history, current status, and clinic promise of ongoing advances in basal insulin analogs and insulin delivery devices.

The controversial role postprandial glucose (PPG)— spikes in blood sugar levels after eating—plays in overall hyperglycemia and in the development of diabetes complications in patients with is the focus of an article by Louis Monnier, MD, Claude Colette, PhD, and David Owens, MD, University of Montpellier (France) and University Hospital Llandough (Cardiff, United Kingdom), entitled "Postprandial and Basal Glucose in Type 2 Diabetes: Assessment and Respective Impacts."

Geremia Bolli, MD, Anna Marinelli Andreoli, MD, and Paola Lucidi, MD, PhD, University of Perugia (Italy), review the critical role of basal insulin in maintaining normal and explain the importance of optimizing basal insulin substitution in individuals with type 1 diabetes. The authors explore the advantages and limitations of the most recent options for basal insulin substitution, including long-acting insulin analogs and continuous subcutaneous insulin infusion. In the article "Optimizing the Replacement of Basal Insulin in Type 1 Diabetes Mellitus: No Longer an Elusive Goal in the Post-NPH Era," the authors conclude that modern physiological basal insulin replacement, combined with other standards of care and patient and physician education, make optimal blood sugar and HbA1c control a realistic target of diabetes management.

In their Concluding Remarks on "The Future of Basal Insulin Supplementation," Airin Simon, MD and J. Hans DeVries, MD, PhD, Academic Medical Centre (Amsterdam, The Netherlands), preview and compare the analogs and patch pumps for subcutaneous insulin delivery that are now in development. The results of ongoing clinical studies are promising, but final trial results (being presented at the American Diabetes Association's annual meeting this week in San Diego) are needed to confirm their safety, efficacy, and cost effectiveness.

More information: The articles are available free online at http://www.liebertonline.com/dia

Related Stories

Recommended for you

Snail fever progression linked to nitric oxide production

September 14, 2017
Bilharzia, caused by a parasitic worm found in freshwater called Schistosoma, infects around 200 million people globally and its advance can lead to death, especially in children in developing countries.

Systems analysis points to links between Toxoplasma infection and common brain diseases

September 13, 2017
More than 2 billion people - nearly one out of every three humans on earth, including about 60 million people in the United States - have a lifelong infection with the brain-dwelling parasite Toxoplasma gondii.

Study clears important hurdle toward developing an HIV vaccine

September 13, 2017
An international team of researchers has demonstrated a way of overcoming one of the major stumbling blocks that has prevented the development of a vaccine against HIV: the ability to generate immune cells that stay in circulation ...

As 'flesh-eating' Leishmania come closer, a vaccine against them does, too

September 13, 2017
Parasites that ulcerate the skin, can disfigure the face, and may fatally mutilate its victim's internal organs are creeping closer to the southern edges of the United States.

Promising clinical trial results could give doctors a new tool against drug-resistant strains of malaria parasite

September 13, 2017
Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published in the latest issue of The Lancet Infectious ...

Semen harbors wide range of viruses

September 13, 2017
(HealthDay)—Human semen provides a potential hiding place and breeding ground for a host of dangerous viruses, a new evidence review reports.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.